Spain’s New HTA Royal Decree: Key Changes at a Glance

Spain has approved Royal Decree 415/2026, creating the country's first comprehensive national framework for Health Technology Assessment (HTA). The reform aligns Spain with the EU HTA Regulation while introducing significant changes to how healthcare technologies are evaluated and adopted within the National Health System (SNS).

Expanded Scope of HTA

The new framework extends beyond medicines and medical devices to include:

• Diagnostic tests and in vitro diagnostics
• Digital health technologies and digital therapeutics
• Artificial intelligence applications
• Clinical procedures
• Preventive interventions
• Healthcare organisational models

This reflects a broader approach to evaluating healthcare innovation across the system.

Alignment with EU Joint Clinical Assessments

For medicines that have undergone an EU Joint Clinical Assessment (JCA), Spain will no longer duplicate evaluations of clinical effectiveness and safety.

National assessments will instead focus on areas such as:

• Economic impact
• Social value
• Ethical considerations
• Organisational impact
• Environmental sustainability

Greater Focus on Value Assessment

Technologies will be assessed against existing standards of care rather than on safety and efficacy alone.

Evaluations will consider:

• Added clinical value
• Innovation
• Economic impact
• Social and ethical implications
• Environmental impact
• Healthcare system sustainability

The decree also introduces gender considerations as a formal assessment domain.

Increased Transparency Requirements

Developers may be required to provide information on:

• Public funding received during development
• Development and production costs
• Economic models supporting submissions

Budget impact analyses will become a core component of assessments.

Stronger Industry Participation

The final text grants developers greater procedural rights, allowing companies to formally comment on draft evaluations through a structured consultation process.

Non-Binding Evaluations

One notable change from earlier drafts is the removal of the term "mandatory" from HTA evaluations.

The final decree states that assessments are non-binding, reducing concerns that HTA could become a procedural barrier to pricing and reimbursement decisions.

Real-World Evidence and Lifecycle Assessment

The framework places greater emphasis on real-world evidence and ongoing monitoring of technologies after adoption.

Technologies may be reassessed as new evidence emerges, potentially leading to:

• Revised positioning
• Restricted use
• Disinvestment decisions
• Adoption of newer alternatives

New HTA Governance Structure

The decree establishes three core bodies:

• Governance Council – responsible for strategic oversight and methodology.
• Evaluation Offices – led by AEMPS for medicines and RedETS for non-pharmaceutical technologies.
• Adoption Group – bridges scientific assessment and decision-making, while not replacing existing pricing and reimbursement authorities.

The final decree also increases representation from the Ministries of Finance, Economy, and Industry within the HTA governance structure.

Implementation Timelines

The new system will be introduced over a one-year transition period.

For medicines, assessments are expected to be completed within approximately 70 working days for clinical evaluation and 70 working days for non-clinical evaluation, with a 15-working-day pathway available where an EU Joint Clinical Assessment exists.

Implications and unanswered questions

• Value assessment- Further clarity will be needed on how Spain intends to define and apply the concept of "added clinical value," particularly for technologies assessed through the EU Joint Clinical Assessment process. The extent to which this exercise is used to inform positioning and reimbursement decisions, rather than revisit clinical conclusions and potentially requesting additional evidence submissions from manufacturers, remains to be seen.
• Regional autonomy and access- Spain's healthcare system remains highly decentralised, and the decree does not remove the competencies of the Autonomous Communities. Although national HTA evaluations are intended to provide a common evidence base, the non-binding nature of assessment outcomes raises questions about uniform access across the nation. It remains unclear to what extent the new framework will reduce differences in patient access to medicines and technologies across regions, or whether local budgetary and policy considerations will continue to drive divergent implementation decisions.
• The role of real-world evidence - The increased emphasis on real-world evidence and lifecycle reassessment introduces a more dynamic approach to value assessment. However, questions remain regarding the consequences of positive reassessments. If post-launch data demonstrate greater clinical benefit than originally anticipated, it is not yet clear whether this could support a re-evaluation of pricing, reimbursement conditions, or confidential discount agreements. Conversely, negative findings could strengthen the case for price reductions, tighter access restrictions, or disinvestment decisions.
• Operationalisation of reassessment- The decree provides the legal framework for periodic reassessment, but further guidance will be needed on the triggers, methodologies, and decision-making processes that will govern these reviews. The extent to which reassessments influence pricing and funding decisions remains uncertain.

Overall, the Royal Decree represents a significant evolution of Spain's HTA system, creating opportunities for more coordinated, evidence-based decision-making while also introducing new complexities around implementation, reassessment, and stakeholder engagement. The ultimate impact of the reforms will depend not only on the legislation itself but on how the framework is applied in practice over the coming years.

Lightning Health closely monitors the developments across EU Joint Clinical Assessments, national HTA frameworks, and medtech market access. If you'd like to discuss the implications for your portfolio or access strategy, get in touch at enquiries@lightning.health.

Article by Orla Mckay

‍